Literature DB >> 8568803

High-affinity partial agonist imidazo[1,5-a]quinoxaline amides, carbamates, and ureas at the gamma-aminobutyric acid A/benzodiazepine receptor complex.

E J Jacobsen1, R E TenBrink, L S Stelzer, K L Belonga, D B Carter, H K Im, W B Im, V H Sethy, A H Tang, P F VonVoigtlander, J D Petke.   

Abstract

A series of imidazo[1,5-a]quinoxaline amides, carbamates, and ureas which have high affinity for the gamma-aminobutyric acid A/benzodiazepine receptor complex was developed. Compounds within this class have varying efficacies ranging from antagonists to full agonists. However, most analogs were found to be partial agonists as indicated by [35S]TBPS and Cl- current ratios. Many of these compounds were also effective in antagonizing metrazole-induced seizures in accordance with anticonvulsant and possible anxiolytic activity. Selected quinoxalines displayed limited benzodiazepine-type side effects such as ethanol potentiation and physical dependence in animal models. Dimethylamino urea 41 emerged as the most interesting analog, having a partial agonist profile in vitro while possessing useful activity in animal models of anxiety such as the Vogel and Geller assays. In accordance with its partial agonist profile, 41 was devoid of typical benzodiazepine side effects.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8568803     DOI: 10.1021/jm940765f

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  Characterization of Tunable Radical Metal-Carbenes: Key Intermediates in Catalytic Cyclopropanation.

Authors:  Jonathan L Belof; Christian R Cioce; Xue Xu; X Peter Zhang; Brian Space; H Lee Woodcock
Journal:  Organometallics       Date:  2011-04-29       Impact factor: 3.876

2.  A practically simple, catalyst free and scalable synthesis of N-substituted ureas in water.

Authors:  Lata Tiwari; Varun Kumar; Bhuvesh Kumar; Dinesh Mahajan
Journal:  RSC Adv       Date:  2018-06-13       Impact factor: 4.036

Review 3.  Generalised anxiety disorder: treatment options.

Authors:  John J Sramek; Victoria Zarotsky; Neal R Cutler
Journal:  Drugs       Date:  2002       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.